Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS

B. Tombal,F. Saad,K. Fizazi,C. N. Sternberg,E. D. Crawford, C. Gratzke, M. Grabbert, A. Vilaseca, N. Shore, E. Kopyltsov, M. Boegemann, S. Kapur, S. Srinivasan, F. Verholen, I. Kuss, H. Joensuu,M. R. Smith,M. Hussain

EUROPEAN UROLOGY(2023)

引用 0|浏览9
暂无评分
关键词
Metastatic Prostate Cancer
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要